NCT07217496 2026-03-17N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial CancerUniversity of California, San FranciscoPhase 1 Withdrawn
NCT03197571 2025-02-21QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyImmunityBio, Inc.Phase 1/2 Withdrawn